Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction

European Journal of Heart Failure

Volumn 17, Issue 10, 2015, Pages 1006-1014

  Sanders Van Wijk, S ^a   Van Empel, V ^a   Davarzani, N ^a,b   Maeder, M T ^c   Handschin, R ^d   Pfisterer, M E ^e   Brunner La Rocca, H P ^a,e  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d University Hospital Bruderholz   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarkers; Heart failure; Natriuretic peptide; Preserved left ventricular function; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CYSTATIN C; HEMOGLOBIN; INTERLEUKIN 1 RECEPTOR; LOOP DIURETIC AGENT; RENIN INHIBITOR; SPIRONOLACTONE; TROPONIN T; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; FUNCTIONAL STATUS; GENDER; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HOSPITALIZATION FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRESERVED HEART LEFT VENTRICLE EJECTION FRACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REDUCED HEART LEFT VENTRICLE EJECTION FRACTION; REFERENCE VALUE; SURVIVAL; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; BLOOD; CLINICAL TRIAL; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; PROGNOSIS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84945960082     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.414     Document Type: Article

References (40)

1. Maeder MT, Kaye DM,. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2009; 53: 905-918.
2. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, Slama M, Massy Z,. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008; 29: 339-347.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, Veldhuisen DJ, Atar D, Hoes AW,. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008; 10: 933-989.
4. Paulus WJ, Tschope C,. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-271.
5. van Empel VP, Kaye DM,. Integration of exercise evaluation into the algorithm for evaluation of patients with suspected heart failure with preserved ejection fraction. Int J Cardiol 2013; 168: 716-722.
6. Parekh N, Maisel AS,. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol 2009; 24: 155-160.
7. Daniels LB, Maisel AS,. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
8. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, Persson H, O'Connor CM, Moertl D, Karlstrom P, Dahlstrom U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG,. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014; 35: 1559-1567.
9. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, Boersma E, Kardys I,. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013; 15: 1350-1362.
10. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M, Investigators TC,. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 2006; 151: 949-955.
11. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP, TIME-CHF Investigators,. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301: 383-392.
12. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
13. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
14. https://gephi.org/
15. Santhanakrishnan R, Chong JP, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Richards AM, Lam CS,. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012; 14: 1338-1347.
16. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL,. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61: 1498-1506.
17. Bishu K, Deswal A, Chen HH, LeWinter MM, Lewis GD, Semigran MJ, Borlaug BA, McNulty S, Hernandez AF, Braunwald E, Redfield MM,. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 2012; 164: 763-770 e3.
18. de Denus S, Lavoie J, Ducharme A, O'Meara E, Racine N, Sirois MG, Neagoe PE, Zhu L, Rouleau JL, White M,. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. Can J Cardiol 2012; 28: 62-68.
19. Quiroz R, Doros G, Shaw P, Liang CS, Gauthier DF, Sam F,. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol 2014; 113: 691-696.
20. Stahrenberg R, Edelmann F, Mende M, Kockskamper A, Dungen HD, Luers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R,. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010; 12: 1309-1316.
21. Niethammer M, Sieber M, von Haehling S, Anker SD, Munzel T, Horstick G, Genth-Zotz S,. Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int J Cardiol 2008; 129: 111-117.
22. Wisniacki N, Taylor W, Lye M, Wilding JP,. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005; 91: 32-37.
23. Michowitz Y, Arbel Y, Wexler D, Sheps D, Rogowski O, Shapira I, Berliner S, Keren G, George J, Roth A,. Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol 2008; 125: 347-351.
24. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL,. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011; 107: 259-267.
25. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK,. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-2512.
26. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, Dargie HJ,. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86: 21-26.
27. Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, Martinez-Marcos FJ, Camacho-Vazquez C, Ruiz-Frutos C, Pujol-De La Llave E,. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 2011; 17: 31-38.
28. Casado J, Montero M, Formiga F, Carrera M, Urrutia A, Arevalo JC, Perez-Calvo JI, Investigators R,. Clinical characteristics and prognostic influence of renal dysfunction in heart failure patients with preserved ejection fraction. Eur J Intern Med 2013; 24: 677-683.
29. McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, Gotsman I, Whalley G, Earle N, Poppe KK, Doughty RN, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) Investigators. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012; 5: 309-314.
30. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM,. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE Trial. Circ Heart Fail 2011; 4: 569-577.
31. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E,. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 2008; 102: 733-737.
32. Maeder MT, Rickenbacher P, Rickli H, Abbuhl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP, TIME-CHF Investigators,. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail 2013; 15: 1148-1156.
33. Iqbal N, Alim KS, Aramin H, Iqbal F, Green E, Higginbotham E, Maisel AS,. Novel biomarkers for heart failure. Expert Rev Cardiovasc Ther 2013; 11: 1155-1169.
34. van Kimmenade RR, Januzzi JL Jr., Emerging biomarkers in heart failure. Clin Chem 2012; 58: 127-138.
35. Rehman SU, Mueller T, Januzzi JL,. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52: 1458-1465.
36. Latado AL, Passos LCS, Darzé ES, Lopes AA,. Comparison of the effect of anemia on in-hospital mortality in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol 2006; 98: 1631-1634.
37. Perna ER, Aspromonte N, Cimbaro Canella JP, Di Tano G, Macin SM, Feola M, Coronel ML, Milani L, Parras JI, Milli M,. Minor myocardial damage is a prevalent condition in patients with acute heart failure syndromes and preserved systolic function with long-term prognostic implications. A report from the CIAST-HF (Collaborative Italo-Argentinean Study on Cardiac Troponin T in Heart Failure) study. J Card Fail 2012; 18: 822-830.
38. Izumiya Y, Hanatani S, Kimura Y, Takashio S, Yamamoto E, Kusaka H, Tokitsu T, Rokutanda T, Araki S, Tsujita K, Tanaka T, Yamamuro M, Kojima S, Tayama S, Kaikita K, Hokimoto S, Ogawa H,. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014; 30: 338-344.
39. Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE, Komajda M, Massie BM, McKelvie RS, McMurray JJ, Zile MR, Anand IS,. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 2011; 4: 561-568.
40. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL,. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 2008; 118: 625-31.